Pneumocystis jirovecii pneumonia induced by low-dose methotrexate in a patient with chronic urticaria

Wang, Sheng-Huei; Tang, Shou-Hung; Li, Yu-Huei; Wei, Kuang‐Yu; Chang, C.

doi:10.1590/abd1806-4841.20175392

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumocystis jirovecii pneumonia has been reported in a patient with refractory chronic urticaria receiving low-dose weekly methotrexate treatment. 9 Hepatic dysfunction has been reported in a child with use of high dose methotrexate. 10 In a randomized, placebo-controlled double-blind trial 11 for the treatment of H1 antihistamine-resistant chronic spontaneous urticaria, methotrexate failed to show any additional benefit over H1 antihistamines.…”

Section: Introductionmentioning

confidence: 99%

“…Although well tolerated, use of methotrexate can be associated with adverse events in some patients. Pneumocystis jirovecii pneumonia has been reported in a patient with refractory chronic urticaria receiving low‐dose weekly methotrexate treatment 9 . Hepatic dysfunction has been reported in a child with use of high dose methotrexate 10 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of methotrexate as add on therapy to H1 antihistamine in difficult to treat chronic urticaria: A systematic review and meta‐analysis of randomized clinical trials

Patil

Bingewar²,

Goldust

2020

Dermatologic Therapy

View full text Add to dashboard Cite

A systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate efficacy of add on methotrexate in chronic urticaria. "PubMed" and "Google Scholar" were systematically searched to identify randomized clinical trials with methotrexate in patients with chronic urticaria not responding to second generation antihistamines. Odds ratios and 95% confidence interval were calculated for estimation of efficacy. Heterogeneity among studies was tested using Tau squared (τ 2) and I 2. Two RCTs (n = 104) were included. For primary outcome that is, complete remission at 18 weeks in Leducq et al study and patients achieving more than two third reduction in wheal score that is, one of the primary outcomes in Sharma et al study there was no significant difference in methotrexate vs placebo (OR [95%CI] 1.64[0.34, 7.90]). There was no significant difference for complete remission at 18 weeks in Leducq et al study and patients achieving more than two third reduction in the pruritus score (one of the primary outcomes in Sharma et al study) (OR [95%CI] 1.03 [0.24, 4.38]) too. In both studies, methotrexate was well tolerated. There was no significant benefit of add on methotrexate to antihistamine in the treatment of difficult to treat urticaria. Inclusion of only two randomized controlled trials is the limitation of this meta-analysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%